Hammarskiöld acted as legal adviser to Devyser Diagnostics AB (publ) (Devyser Diagnostics) in connection with its private placement of 7,465 newly issued shares, corresponding to SEK 130 million, to Swedbank Robur and Fjärde AP-fonden. Carnegie Investment Bank acted as financial adviser in connection with the private placement. As part of the private placement, Swedbank Robur and Fjärde AP-fonden subscribed for shares valued at SEK 80 million and SEK 50 million, respectively. Following the issue, they will hold 12 percent and 8 percent, respectively, of the total number of shares and voting rights in Devyser Diagnostics, becoming the company’s second and fifth largest owners.
Devyser Diagnostics is specialised in the development, manufacture and sale of market-leading genetic diagnostic kits in over 60 countries. Development and manufacturing take place in Sweden while sales are conducted from the company’s offices in Sweden, Germany and Italy. The company has reported annual growth (CAGR) in excess of 30 percent since 2016 and with a positive EBIT.
Hammarskiöld’s team primarily consisted of:
Malin Albert (Partner)
Carl-Johan Pousette (Partner)
Aksel Ahlqvist (Associate)
